OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2024-05-06
- Target Recruit Count
- 570
- Registration Number
- NCT05428033
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard
- Conditions
- Interventions
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 31
- Registration Number
- NCT05402111
- Locations
- 🇺🇸
Woodland Research Northwest, LLC, Rogers, Arkansas, United States
🇺🇸Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Collaborative Neuroscience Research, LLC, Long Beach, California, United States
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-07-17
- Target Recruit Count
- 700
- Registration Number
- NCT05279313
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder
- Conditions
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-09-27
- Target Recruit Count
- 459
- Registration Number
- NCT05257265
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-12-09
- Target Recruit Count
- 600
- Registration Number
- NCT05248659
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)
- Conditions
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-03-26
- Target Recruit Count
- 530
- Registration Number
- NCT05248646
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-06-27
- Target Recruit Count
- 122
- Registration Number
- NCT05221502
- Locations
- 🇿🇦
Aurum Institute - Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa
🇿🇦TASK Applied Science, Brooklyn Chest Hospital Premises, Cape Town, South Africa
🇿🇦University of CapeTown Lung Center Institute, Cape Town, South Africa
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
- Conditions
- Interventions
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2024-01-23
- Target Recruit Count
- 34
- Registration Number
- NCT05189977
- Locations
- 🇺🇸
For additional information regarding sites (California, Texas, New Jersey, Minnesota), Princeton, New Jersey, United States
A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2023-09-01
- Target Recruit Count
- 147
- Registration Number
- NCT05113953
- Locations
- 🇺🇸
iResearch Atlanta, Decatur, Georgia, United States
🇺🇸Psych Atlanta, PC, Marietta, Georgia, United States
🇺🇸Princeton Medical Institute, Princeton, New Jersey, United States
Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2023-06-13
- Target Recruit Count
- 50
- Registration Number
- NCT05066724
- Locations
- 🇺🇸
Rose Research Center, Raleigh, North Carolina, United States